Skip to content

Menu

About Us
Our Science
Newsroom
- Press Releases
- Events & Presentations
Investor Relations
Contact

Close Menu

Our Science

Overview of Assets
Science
– Polyamines
– Polyamine Metabolic Inhibitor Technology
Pipeline
Clinical Trials
– Ivospemin
– Flynpovi
Expanded Access Policy

Quick Links

Home
About Us
Our Science
Newsroom
Investor Relations
Contact

Contact

ir@panbela.com

Sign up to receive press releases via email:

Leave this field empty if you're human:

News & Events

Panbela Announces Publication of Abstract: Evaluation of Myeloma Cell Lines Viability Following Administration of SBP-101 and DFMO Polyamine Inhibitors

Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification

Panbela Provides Business Update and Reports Q3 2023 Financial Results

Copyright ©2023 Panbela Therapeutics, Inc. All Rights Reserved.